Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Cutaneous 5Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Mycosis Fungoides 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia 3Congenital Abnormalities 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sezary Syndrome 2Sarcoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lung Neoplasms 2Leukemia, Promyelocytic, Acute 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Colorectal Neoplasms 2Burkitt Lymphoma 2Breast Neoplasms 2Astrocytoma 2Waldenstrom Macroglobulinemia 1

Interventions

Doxorubicin 4Cyclophosphamide 4fludarabine phosphate 3Vorinostat 3Vincristine 3Etoposide 3Rituximab 2Prednisone 2Pharmacogenomic Testing 2MK 2206 2Cyclosporine 2Busulfan 2Bortezomib 2Bevacizumab 2Antilymphocyte Serum 2veliparib 1vandetanib 1temsirolimus 1tanespimycin 1siplizumab 1romidepsin 1obatoclax 1liposomal doxorubicin 1gossypol acetic acid 1ganitumab 1fludarabine 1duvelisib 1cediranib 1cc-486 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Extranodal NK-T-Cell × romidepsin × Clear all
NCT04639843 2022-11-04

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡